Method of promoting nucleic acid transfer

• US 8,742,091 B2
• Filed: 06/20/2002
• Issued: 06/03/2014
• Est. Priority Date: 06/20/2001
• Status: Active Grant

• Current Assignee: National Cancer Center, Sumitomo Pharma Co Ltd (Sumitomo Chemical Company Limited)
• Original Assignee: Koken Limited, National Cancer Center, Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited)
• Inventors: Terada, Masaaki, Ochiya, Takahiro, Aso, Yu, Honma, Kimi, Sano, Akihiko, Nagahara, Shunji
• Primary Examiner(s): SCHNIZER, RICHARD A
• Application Number:
  US10/481,511
• Publication Number:
  US 20040266004A1
• Time in Patent Office: 4,366 Days
• Field of Search: None
• US Class Current: 536/24.5
• CPC Class Codes: A61K 47/6435 the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

Means for transferring efficiently a desired nucleic acid into a cell is provided.

The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.

Claims

1. A pharmaceutical preparation for administration to a living body comprising a solution of an electrostatic complex consisting essentially of a double-stranded RNA and a water-soluble atelocollagen, wherein said complex facilitates the transfer of said double-stranded RNA to a target tissue or a target organ and said complex exhibits a major axis of 100 μ

m or less in length.

2. The preparation according to claim 1, wherein the double-stranded RNA is 5-30 nucleotides in length.

3. The preparation according to claim 1, wherein the double-stranded RNA is an RNA derivative.

4. The preparation according to claim 1, wherein the double-stranded RNA is an RNA comprising a phosphorothioate bond.

5. The preparation according to claim 1, wherein the double-stranded RNA is an RNA comprising an internucleotide comprising a phosphate, sugar or base moiety chemically modified to avoid enzymatic degradations.

6. A pharmaceutical preparation for administration to a living body comprising a solution of an electrostatic complex consisting essentially of an a double-stranded RNA and a water-soluble atelocollagen, wherein said complex facilitates the transfer of said double-stranded RNA to a target tissue or a target organ and said complex exhibits a major axis of 10 μ

m or less in length.

7. The preparation according to claim 6, wherein the double-stranded RNA is 5-30 nucleotides in length.

8. The preparation according to claim 6, wherein the double-stranded RNA is an RNA derivative.

9. The preparation according to claim 6, wherein the double-stranded RNA is an RNA comprising a phosphorothioate bond.

10. The preparation according to claim 6, wherein the double-stranded RNA is an RNA comprising an internucleotide comprising a phosphate, sugar or base moiety chemically modified to avoid enzymatic degradations.